Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has today unveiled two access schemes which will enable more academically talented students from under-represented backgrounds to successfully apply to study.

© Panoramic view of Oxford Credit: Sheng Peng

The combined impact of the ambitious programmes represents a major progression for the University, with one Oxford undergraduate in four set to be from the UK’s most under-represented backgrounds by 2023.

The two new programmes – Opportunity Oxford and Foundation Oxford – aim to increase significantly the number of most promising students from groups who are currently under-represented in Oxford. Opportunity Oxford is aimed at students from more disadvantaged socio-economic backgrounds. Foundation Oxford will be open to students who have personally experienced severe disadvantage or educational disruption.

When fully up and running, these major new programmes will offer transformative paths to outstanding education for up to 250 state school students a year, representing 10% of Oxford’s UK undergraduate intake. This represents a significant step change for the University, boosting the proportion of students coming to Oxford from under-represented backgrounds from 15% of the current UK intake to 25%.

Find out more (University of Oxford website)

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.